Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02224690 · ClinicalTrials.gov registry record · Phase 3

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

A Phase 3 study of Epilepsy and Lennox Gastaut Syndrome, sponsored by Jazz Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
171
Enrollment target
20
Study locations

NCT02224690 is a Phase 3 study of Epilepsy and Lennox Gastaut Syndrome that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 171 participants, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02224690, a Phase 3 study of Epilepsy and Lennox Gastaut Syndrome, has completed, sponsored by Jazz Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
171 participants
Enrollment target
20
Study locations

Study Summary

To evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo, in participants with Lennox-Gastaut Syndrome (LGS).

Conditions Studied

Epilepsy Lennox Gastaut Syndrome

Interventions

  • DRUG Placebo
  • DRUG GWP42003-P 20 mg/kg/day Dose

Study Locations (20)

Iowa

  • - Ames
  • - Iowa City

New York

  • - Rochester
  • - The Bronx

Texas

  • - Dallas
  • - Houston

Other

  • - Bydgoszcz
  • - Gdansk

Florida

  • - Tampa

Georgia

  • - Atlanta

Illinois

  • - Chicago

Kentucky

  • - Lexington

Trial Details

FieldValue
Enrollment Target 171 participants
Start Date 2015-04-28
Est. Completion 2016-03-18
Phase Phase 3

Sponsor

Jazz Pharmaceuticals

128 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02224690

The ClinicalTrials.gov registry entry for NCT02224690 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (82% lower). The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02224690 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Iowa, New York, Texas.

Frequently Asked Questions

What is clinical trial NCT02224690 about?

NCT02224690 is a clinical study titled "A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults". To evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo, in participants with Lennox-Gastaut Syndrome (LGS).

What is the current status of trial NCT02224690?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 171 participants. The study started on 2015-04-28. Estimated completion is 2016-03-18.

What conditions does trial NCT02224690 study?

This clinical trial studies the following conditions: Epilepsy, Lennox Gastaut Syndrome.

What interventions are being tested in trial NCT02224690?

The interventions under investigation include: Placebo (DRUG), GWP42003-P 20 mg/kg/day Dose (DRUG).

Who is sponsoring clinical trial NCT02224690?

This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02224690 being conducted?

This trial has 20 study locations across Florida, Georgia, Illinois, Iowa, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Epilepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Epilepsy

All registered trials for this condition

Lennox Gastaut Syndrome

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.